TELA Bio Inc(TELA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.77 | Insider Own | 25.99% | Shs Outstand | 44.8M | Perf Week | -16.05% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 35.67% | Insider Trans | 1.54% | Shs Float | 33.4M | Perf Month | -35.19% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -0.16 | Inst Own | 39.93% | Short Float | 1.91% | Perf Quarter | 9.47% |
| Income | -0.04B | P/S | 0.46 | EPS this Y | 16.97% | Inst Trans | -5.93% | Short Ratio | 2.83 | Perf Half Y | -18.1% |
| Sales | 0.08B | P/B | - | EPS next 5Y | 26.12% | ROA | -64.71% | Short Interest | 0.64M | Perf YTD | -31.35% |
| Book/sh | -0.35 | P/C | 1.2 | EPS past 3/5Y | 32.78% 17.97% | ROE | -616.62% | 52W High | -45.99% ($1.50) | Perf Year | -37.68% |
| Cash/sh | 0.67 | P/FCF | - | Sales past 3/5Y | 24.68% 34.54% | ROIC | -102.4% | 52W Low | 61.66% ($0.50) | Perf 3Y | -86.08% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 30.65% | Gross Margin | 67.81% | Volatility(W/M) | 10.2% 11.31% | Perf 5Y | -93.71% |
| Dividend TTM | - | EV/Sales | 0.79 | Sales Y/Y TTM | 6.09% | Oper. Margin | -42.56% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.38 | EPS Q/Q | 10.29% | Profit Margin | -51.53% | RSI (14) | 33.47 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.99 | Sales Q/Q | -4.49% | SMA20 | -20.76% ($1.02) | Beta | 1.42 | Target Price | $1.9 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/10 | SMA50 | -19.62% ($1.01) | Rel Volume | 1.46 | Prev Close | $0.92 |
| Employees | 218 | LT Debt/Eq | - | EPS/Sales Surpr. | -15.07% -3.59% | SMA200 | -5.46% ($0.86) | Avg Volume(3M) | 0.23M | Price | $0.81 |
| IPO | 2019/11/8 | Option/Short | Yes/Yes | Trades | 373 | Volume | 330,115 | Change | -11.95% |
🩺 TELA Bio () is a medical device company based in Pennsylvania, USA, that specializes in biologic reinforcement mesh (OviTex) products used for hernia repair and soft tissue reconstruction. The OviTex product line, which received FDA approval in 2016, is differentiated by its composite structure that combines ovine (sheep)‑derived extracellular matrix with synthetic fibers.
Over the past 1 year, roughly in the middle
46% below its 1-year high.
Traded more than usual. That is 146% of its average volume.
Next earnings report: November 10
8 days to go.
TELA has a sound balance sheet but weak earning power
Of every $100 in sales, $42.56 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +17.0% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $46. Peers typically go for $143.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.7%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 39.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #103 of 142 in the industry
Based on market cap of $37M.
FAQ
What kind of company is TELA?
TELA belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of TELA?
The market cap of TELA is approximately $37M, ranking 4,996 within its sector.
What is the 52-week high and low for TELA?
TELA has recorded a 52-week high of $1.50 and a low of $0.50.
